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Abstract
Membrane cofactor protein (MCP; CD46) is an ubiquitously expressed complement regulatory protein that protects
host cells from injury by complement. This type-I membrane glycoprotein serves as a cofactor for the serine protease
factor I to mediate inactivation of C3b and C4b deposited on host cells. More than 60 disease-associated mutations in
MCP have now been identified. The majority of the mutations are linked to a rare thrombotic microangiopathic-based
disease, atypical hemolytic uremic syndrome (aHUS), but new putative links to systemic lupus erythematosus,
glomerulonephritis, and pregnancy-related disorders among others have also been identified. This review summarizes
our current knowledge of disease-associated mutations in this complement inhibitor.
Keywords: CD46, Membrane cofactor protein, Complement, Complement regulation, Atypical hemolytic uremic
syndrome
Introduction
The complement system is one of the most ancient com-
ponents of innate immunity. It likely evolved from a C3-
like protein that was cleaved by proteases into biologically
active self-defense fragments to counteract invading mi-
crobes, particularly bacteria, and to clear biologic debris
(self and foreign) [1, 2]. The development of a circulatory
system may have been the key evolutionary pressure that
drove the need for a rapidly acting (within seconds) innate
immune host-defense process with the destructive power
to prevent invasion and multiplication of bacteria in the
blood stream [3]. The complement system is sometimes
referred to as “the guardian of the intravascular space”.
The vertebrate-complement system consists of a set of
sequentially interacting proteins featuring three major
pathways that provide a swift and powerful host-defense
system. It promotes the inflammatory response and me-
diates the identification and destruction of pathogens. This
is accomplished in two major ways (Fig. 1). First, comple-
ment modifies the membranes of microbes. Activated
fragments are covalently deposited in large amounts on
microorganisms, immune complexes, and damaged tissue.
For example, several million C3-derived activation frag-
ments can attach in clusters to a bacterial surface in less
than five minutes. The most important function of these
covalently deposited complement proteins is to opsonize
the target, thus serving as ligands for complement recep-
tors on peripheral blood cells; specifically, erythrocytes,
neutrophils, B lymphocytes and monocytes, as well as
dendritic cells, and tissue monocytes. The receptors serve
to bind (immune adherence), internalize (in some cases),
transport, and clear the microbe. Additionally, the mem-
branes of some pathogens (especially gram-negative bac-
teria) can be disrupted by the terminal-complement
components (membrane-attack complex, MAC) leading
to osmotic lysis.
The second function of complement is to promote the
inflammatory response. Thus, peptides, released by pro-
teolysis during complement activation, bind to receptors
to elicit an inflammatory reaction. These peptides are
termed anaphylatoxins because they can trigger the re-
lease of mediators such as histamine to cause shock.
Due to its proinflammatory and destructive capabil-
ities, it is no surprise that nearly half of the complement
proteins serve in its regulation. Unimpeded, the comple-
ment system fires to exhaustion, a point illustrated by
inherited deficiencies of its regulatory proteins [4, 5].
These inhibitors also participate in “self” versus “nonself”
discrimination in that foreign surfaces, usually lacking
such regulators, are recognized and attacked, while healthy
self-tissues expressing the regulators are protected.
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The alternative pathway (AP) continuously turns over,
generating C3 fragments. If a C3b lands on host cells, it
must be inactivated by regulatory proteins. One such
control protein, CD46 (membrane cofactor protein;
MCP), is a member of a group of genetically-, structurally-
, and functionally-related proteins called the regulators of
complement activation (RCA) [6, 7]. As its name implies,
the goal of this gene cluster of receptors and inhibitors is
to provide homeostasis by tightly controlling the rapid
and powerful amplification process of the AP in order
to focus complement attack, in both time and space, on
pathogens and, in a more homeostatic manner, injured
tissue.
Recently identified associations of human disease featur-
ing excessive AP activation with heterozygous mutations
in its components and regulators and the development of
a novel therapeutic agent to block C5 cleavage have reig-
nited interest in the field [8, 9].
This review focuses on the ubiquitously expressed in-
hibitor of C3b and C4b, CD46, and the primary diseases
associated with its dysfunction. Citations included are
not meant to be exhaustive, but rather to provide key re-
view articles.
Complement pathways
More than a billion years ago, primitive elements of the
complement system arose to form a humoral immune
system likely derived by proteolysis of a primeval protein
whose fragmentation released one piece to mediate
opsonization and a second one to elicit an inflammatory
response [1, 10–12]. This original pathway (that remains
today with enhanced sophistication and inappropriately
called the AP) provided a simple protein-based recogni-
tion and effector scheme against pathogens. Lectins and
antibodies, representing subsequent evolutionary develop-
ments, became connected to the complement-dependent
effector mechanisms of opsonization and membrane per-
turbation. As the system grew in capacity and efficiency,
control mechanisms were required to maintain homeosta-
sis and to focus attack on pathogens while minimizing
damage to self.
The contemporary human-complement system now
consists of an efficient, interacting set of nearly 60 blood
(serum) and cellular components that include compo-
nents of the activating cascades, receptors, and positive
and negative regulators. Complement systems similar to
that in mammals also have been identified in birds, fish,
amphibians, and reptiles. An AP is also found in more
primitive species, even those lacking a circulatory system
[13]. The complement system consists of three major ac-
tivating pathways that are independently triggered, yet
all have the common goal of modifying the target mem-
brane by depositing C3 activation products and then en-
gaging a common terminal membrane-attack complex
(Fig. 2).
The AP is the most ancient cascade. It does not require
an antibody, a lectin, or prior contact with a pathogen
to become engaged. Indeed, it serves as a rapid, self-
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Fig 1 Complement function. The two primary functions of the complement system are to modify pathogens and self-debris with clusters of
complement fragments (opsonization). This, in turn, facilitates interaction with complement receptors and, in some bacteria and viruses, induces
lysis. The second function is to promote the inflammatory response. Complement fragments C3a and C5a generated during activation of the
cascades stimulate many cell types. In the case of mast cells, release of immunomodulatory granules also attracts phagocytic cells into the area of
inflammation (chemotaxis)
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amplifying, and exceptionally powerful innate immune
system capable of independently recognizing and
destroying foreign targets and promoting an inflamma-
tory response. A small amount of auto-activated C3 (so
called, C3 tickover) is constantly generated in blood
secondary to engagement of its labile thioester bond.
This C3 turnover mechanism serves as a surveillance
system. If it deposits on healthy self, it is inactivated. If
it deposits on a microbe, it can be rapidly amplified.
Thus, in the latter case, C3b sequentially engages two
proteases, factor B (FB) and factor D (FD), and the sta-
bilizing protein properdin (P). These interact to form
an AP C3 convertase (C3bBbP) that cleaves C3 to C3b
and C3a. This system, therefore, represents a powerful
feedback loop for the generation of C3b (Fig. 3).
The classical pathway (CP) was discovered first in the
late 1800s, hence its name. It is primarily triggered by
antibodies (IgM and IgG, subclasses 1 and 3) binding to
antigens. This initiates a cascade featuring multiple pro-
teolytic cleavage steps beginning with the C1s compo-
nent of C1 that cleaves C4 and C2. The newly generated
C4b and C2a fragments then interact to form the C3
convertase, a proteolytic complex that activates C3. This
convertase “converts” C3 into the C3a fragment (an in-
flammatory modulator) and the larger fragment, C3b,
which serves as an opsonin and nidus for a feedback
loop to generate more C3b. In an analogous process, the
LP generates the same C3 convertase, but in this scheme,
lectins substitute for antibodies in binding antigen-like
sugar (mannose) residues, and mannose binding lectin-
associated serine proteases (MASPs) replace C1r and
C1s [14].
All three pathways merge at the step of the generation
of a C3 convertase (Fig. 2). The C3b that deposits on path-
ogens serves both as a ligand for receptors in addition to
being a central component of the feedback loop. Addition
of a second C3b to a C3 convertase generates a C5 conver-
tase. The latter cleaves C5 into a potent anaphylatoxin
(C5a) and the larger C5b fragment. The C5b binds to C6
and C7 (without proteolysis) and this complex attaches to
a membrane. Next, the C5b67 complex binds C8 followed
by multiple C9s (~10–15) to form the MAC (C5b-9)
(reviewed in [15]).
CD46 and the “regulators of complement activation”
gene cluster
Control of complement occurs in the fluid phase (plasma)
and on self-tissue at each of the major steps in the path-
ways: initiation; amplification leading to C3 and then C5
cleavage; and, formation of C5b-C9.
Originally identified as a C3b- and C4b-binding pro-
tein of human peripheral blood cells, CD46 is expressed
Fig. 2 The complement cascades. The three pathways of complement activation are shown. Although each is triggered independently, they
merge at the step of C3 activation. The CP is initiated by the binding of antibody to antigen and the lectin pathway by the binding of lectin to a
sugar. The alternative pathway turns over continuously and possesses a feedback loop (see Fig. 3). Activation of the complement system leads to
inflammation, opsonization, and membrane perturbation. Abbreviations: MASP MBL-associated serine protease, MBL mannose-binding lectin, FB
factor B, FD factor D, P properdin
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as a type-I transmembrane protein on nucleated cells
[16–18]. The MCP gene is located in the regulators of
complement activation (RCA) cluster at 1q3.2 [6, 19].
In addition to CD46, other proteins in this C3/C4-
interacting family are CD35 (complement receptor one;
CR1); CD21 (complement receptor 2, CR2); CD55
(decay-accelerating factor, DAF); C4b binding protein
(C4BP); factor H (FH) and its family of proteins, factor
H-like protein 1 (FHL-1), and factor H-related proteins
1–5 (FHR-1 to 5) [7, 20, 21].
The human RCA gene cluster spans a total of
21.45 cM on the long arm of chromosome 1 and in-
cludes more than 60 genes of which 15 are related to
complement [21]. One group of genes is telomeric in a
900-kb DNA segment and the other is a centromeric 650-
kb fragment. These are separated by a 14–59 cM segment
that includes a number of genes unrelated to complement
[21]. Complement regulatory genes share a common
ancestral motif from which they arose by multiple gene
duplication events [13, 19, 21].
CD46 and other members of the RCA are composed
of a repeating unit that begins at the amino-terminus
and comprises most or all of the protein. This structural
feature, called a complement control protein (CCP)
module (also a short consensus repeat or a sushi do-
main), consists of ~60 amino acids with four invariant
cysteines and 10–18 other highly conserved amino acids.
The CCP modules house the sites for regulatory activ-
ities, i.e., binding sites for C3b, C4b and/or factor I (FI)
that foster cofactor activity (CD46, FH, C4BP, CR1), and
decay-accelerating activity (CD55, FH, C4BP, CR1).
Cofactor activity is the process whereby C3b and
C4b are proteolytically inactivated by FI, a plasma
serine protease. A cofactor protein such as CD46 or
FH must bind to the substrate (C4b or C3b) before FI
can cleave these two large fragments (Fig. 4). Decay-
accelerating activity (DAA) refers to a regulatory
process for enhancing the spontaneous decay of the
convertases. The active protease fragment is dissoci-
ated. CD46 possesses cofactor activity for C4b and C3b
but does not possess DAA.
The gene for CD46 is ~43 kb and contains 14 exons
[6]. A partial duplicate (exons 1–4; MCP-like) has been
identified, but there is no evidence for its expression.
CD46 consists of four major alternatively spliced tran-
scripts [6, 16]. Most cell types express all four of the
proteins in approximately the same ratio as is observed
on peripheral blood cells (although cell-specific isoform
expression has been identified [16, 19]). Each isoform
shares an identical amino-terminal portion consisting of
four CCPs followed by an alternatively spliced region for
O-glycosylation. Although there are three exons coding
for this region (A, B, and C), the four most commonly
expressed isoforms carry B + C or C alone. Next is the
flanking juxtamembraneous 12 amino-acid domain of
unknown significance followed by a hydrophobic trans-
membrane region and a charged cytoplasmic anchor.
The carboxyl-terminal tail is also alternatively spliced. It
contains one of two nonhomologous cytoplasmic tails of
Fig. 3 Feedback loop of the alternative pathway. Following the
attachment of C3b to its target, a feedback loop can be engaged via
interactions with the two proteases, factor B (FB) and factor D (FD), to
form the AP C3 convertase. The binding of properdin (P) stabilizes the
complex (i.e., its half-life is increased from 30–40 s to 3–4 min). Within a
few minutes, more than one million C3bs can be generated and
bound to a single bacterium
Fig. 4 Cofactor activity of CD46 illustrated for the alternative pathway. CD46 binds to C3b that becomes attached to host cells. This then allows the
serine protease factor I to cleave C3b into iC3b that cannot participate in the feedback loop. CD46 is nearly ubiquitously expressed on human cells
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16 or 23 amino acids each of which houses signaling
motifs. The four major isoforms are named CD46-
BC1,−BC2,−C1, and − C2.
CD46 function
In addition to its primary role in the regulation of C3b
and C4b as a membrane cofactor protein, CD46 has been
called the “multitasker” [18] and a “pathogen magnet”
[22]. CD46 is increasingly recognized for its roles in link-
ing innate and adaptive immune responses [17, 18, 23].
Pathogen magnet
The nearly universal expression of CD46 may particu-
larly explain its exploitation by a number of pathogens
who employ it as a receptor, possibly to co-opt one or
more of its complement regulatory activities, signaling
capabilities, or internalization mechanisms (reviewed in
[22]). Nine human-specific pathogens target CD46 in-
cluding four viruses (measles virus, adenovirus groups B
and D, and herpesvirus 6) and five bacterial species
(Neisseria gonorrhoeae, Neisseria meningitidis, Strepto-
coccus pyogenes, Escherichia coli, and Fusobacterium
nucleatum). Additionally, bovine CD46 is a receptor for
bovine viral diarrhea virus, an enveloped RNA virus.
Pathogens target different domains of CD46 for attach-
ment and subsequent reactions. The adenovirus fiber-
knob protein and measles virus hemagglutinin attach to
CCPs 1 and 2. Measles-virus binding elicits internalization
and alters intracellular processing and antigen presenta-
tion (reviewed in [24, 25]). An envelope glycoprotein com-
plex from herpesvirus 6 binds CCPs 2 and 3 (reviewed in
[26]). Following clathrin-mediated endocytosis, the viral
nucleic acid transits to the nucleus and replicates [25].
The type-IV pilus of the Neisseria species targets CCPs 3
and 4 and the STP segment. Neisseria infection causes the
phosphorylation of the cytoplasmic domain (CYT-2) of
CD46 by c-Yes, a member of the Src tyrosine kinase fam-
ily. Studies suggest this phosphorylation is essential for
Neisseria attachment and cytoskeletal rearrangement and
that Neisseria also stimulates proteolytic cleavage of CD46
tails during infection (reviewed in [18, 27]). The M protein
of S. pyogenes, which facilitates invasion of epithelial cells,
attaches to CCPs 3 and 4. On epithelial cells, infection
leads to the shedding of CD46 at the same time as the bac-
teria induce apoptosis and cell death [28]. Furthermore,
interaction of S. pyogenes and CD46 triggers cell signaling
pathways that lead to an immunosuppressive/regulatory
phenotype in T cells (reviewed in [29] and [22]). The bind-
ing site for the periodontal disease-associated F. nucleatum
is unknown [30]. However, the binding of F. nucleatum to
CD46 on epithelial cells contributes to increasing levels of
proinflammatory mediators and matrix metalloproteinases
likely involved in periodontal tissue destruction [30].
Pathogenic microbes also develop their own human-
like proteins to subvert host defenses. Poxviruses express
CD46-like proteins (30–40 % homologous) to control
host complement [31, 32]. Called poxviral inhibitors of
complement enzymes (PICES), proteins from variola,
and monkeypox are named SPICE (smallpox inhibitor of
complement enzymes) and MOPICE (monkeypox in-
hibitor of complement enzymes), respectively [31–34].
They consist of three or four CCPs that are structural
and functional mimics of CD46 and CD55. These viru-
lence factors attach to glycosaminoglycans on the cell
surface via their heparin-binding sites and, thus, down-
regulate the complement system’s ability to attack the
virus [31].
Better understanding of the mechanism by which patho-
gens hijack (e.g., poxviruses) and usurp CD46 function
may also provide greater insights relative to its normal
functional repertoire. Additionally, replication-defective
forms of adenovirus are being utilized in gene transfer and
vaccine clinical trials necessitating a better understanding
of its attachment mechanisms (reviewed in [25]).
Immunomodulatory functions
Over the last 15 years, it has become increasingly ap-
parent that CD46 plays important and surprising
immunomodulatory roles. These studies have been ex-
tensively reviewed particularly in relationship to T-cell
biology (reviewed in [17, 18, 23]). The co-engagement of
the T-cell receptor and CD46 by CD4+ T cells leads to the
induction of interferon-γ (IFN-γ)-secreting effector T-
helper type-1 (Th1) cells (reviewed in [17, 18, 23]). These
subsequently switch predominantly into interleukin-10
(IL-10)-secreting regulatory T cells (Tregs). Thus, a time-
ordered functionally-relevant sequence occurs following
stimulation through CD46; activation initially induces a
rapid burst of interleukin-2 (IL-2) secretion and the gener-
ation of a proinflammatory IFN-γ+/IL-10−T cell phenotype
followed by an intermediate step with IFN-γ+/IL-10+ cells.
The latter then switches to an IFN-γ−/IL-10+ self-
regulatory phenotype (Treg). Recent studies suggest a
possible mechanism for this via the binding by CD46 to a
newly discovered extracellular ligand, Jagged1, a member
of the Notch family of proteins that is regulated by
CD46 [18].
Thus, one could envision that at the outset of an im-
mune response, complement-induced Tregs provide a
supportive role by facilitating B-cell activation via high
IL-10 and sCD40L production (factors required for opti-
mal B-cell activation and Ig class switching). As the im-
mune response progresses, especially with antibody
production and complement-mediated clearance of infec-
tious pathogens, complement-induced Tregs might then
constrain and/or deactivate the immune response.
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Development of a Treg response is important for main-
taining peripheral tolerance and control of immune re-
sponses. Further, T-cell subsets are increasingly recognized
to possess different levels of plasticity in which they ac-
quire new features and functions relative to secondary
or chronic immune responses [35]. Thus, disruption or
alterations of any of these pathways may contribute to
susceptibility to infections or to the development of
autoimmunity. Human diseases implicating defects in
CD46-mediated signaling (reviewed in [17]) are mul-
tiple sclerosis, rheumatoid arthritis, asthma, IPEX-like
syndrome, and primary C3 deficiency. Further, a subset
of CD46-deficient patients develops common variable
immunodeficiency (CVID), a syndrome characterized
by hypogammaglobulinemia [36]. One study demon-
strated that CD46-activated T cells support B-cell acti-
vation and that T cells from a CD46-deficient patient
are impaired in promoting IgG production by B cells
[37]. However, it is as yet unclear how these CD46-
signaling functions play out in human disease.
CD46 variants and disease association
Linkage analyses, genome-wide association studies, and
the recent dramatic progress in next-generation sequen-
cing have revealed an expanding number of disease-
associated genetic alterations in CD46. Specifically, MCP
variants have been increasingly associated with inflam-
matory disorders particularly characterized by the devel-
opment of thrombi in small blood vessels (thombotic
microangiopathy), especially atypical hemolytic uremic
syndrome (aHUS) [38–43].
As expected, a majority of aHUS and other disease-
associated mutations in CD46 occur in the four CCPs,
the extracellular domains responsible for its comple-
ment regulatory activity (Fig. 5 and Tables 1 and 2). An
earlier publication dissecting many of the active sites
of CD46 by mutation modeling demonstrated how crit-
ical amino acids at binding sites lead to a loss-of-
function [44].
Note that there exists confusion in the literature de-
tailing CD46-protein numbering of mutations since
some references include the 34 amino acid signal pep-
tide and all exons of the STP domain (for example, [38,
39, 45, 46]). Others do not include the signal peptide
and/or may leave out the exon of the STP domain that
is a rare protein product (for example, [36, 47, 48]). In
this review, we have adopted the format of numbering
from the translated protein, i.e., the signal peptide and
including all exons of the protein as recommended by
the Human Genome Variation Society.
Overall, two mutations have been identified in the pro-
moter, four in the signal peptide, thirteen in CCP1, nine
in CCP2, fourteen in CCP3, thirteen in CCP4, one in the
STP region, four in the transmembrane domain, and one
in cytoplasmic tail one (CYT-1) (Tables 1 and 2). While
52 mutations are associated with the development of
aHUS, 13 may be associated with other diseases, and
four mutations have been described in several diseases
(see below).
Atypical hemolytic uremic syndrome
Mutation of CD46 has been linked most often to devel-
opment of aHUS. The overall incidence of this rare dis-
order was estimated to be 2 in 1 million (106) in a North
American population (reviewed in [43]). Although aHUS is
characterized by the triad of microangiopathic hemolytic
anemia, thrombocytopenia (lowered platelet count) and
acute renal failure, other organs such as brain, lung, and
gastrointestinal tract can also be affected [38–43, 49] .
Most typical HUS cases (~90 %) are epidemic in nature
featuring diarrhea in association with an enteric infection
from a verocytotoxin-secreting bacteria (e.g., Escherichia
coli O157:H7). Following gastrointestinal infection, most
patients recover, although 5–10 % will progress into
enteropathic or Shigatoxin-producing E. coli (STEC)
HUS, which has a good prognosis for recovery.
In contrast, atypical HUS (aHUS) is a more severe,
non-diarrheal type that results from alternative pathway
over-reaction on endothelial cells, particularly in the kid-
ney. Penetrance is ~50 % with a relapsing and remitting
course resulting in a post-mortality rate in the acute phase
of ~25 %. For survivors, ~50 % will remain dialysis-
dependent. Approximately 60 % of aHUS cases occur dur-
ing childhood, and in a majority, the initial episode occurs
before the age of 2 years (reviewed in [50]). In contrast to
mutations in FH or FI, kidney transplantation for CD46-
deficient individuals has a nearly normal success rate since
the transplanted organ carries a normal level of CD46 ex-
pression [43, 46, 49].
Factors that are reported to precipitate aHUS in-
clude infections, pregnancy, trauma, or drugs. Why
the kidney endothelium is the major site of organ
damage is unknown. What is increasingly clear is that
the fundamental defect in this disease is an inability to
control the AP on damaged or stressed cell surfaces
resulting in excessive and harmful activation on “altered
self”. Dysfunction of mutated proteins can result from
loss-of-function (in regulators responsible for cofactor
activity) or gain-of-function (activating components,
hyperactive C3 convertases). Both lead to inefficiently
degraded C3b and abnormal persistence of C3 and C5
convertases that, in turn, generate excessive amounts of
complement-pathway effectors. Further, C5b initiates the
assembly of the MAC, leading to membrane injury, while
C5a recruits and activates leukocytes and upregulates vas-
cular adhesiveness. With the delicate balance between
complement activation versus complement regulation
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perturbed on endothelial cells, the thrombotic microangi-
opathy ensues with vessel-wall thickening, cell engorge-
ment, and destruction.
Mutations in MCP that predispose to aHUS were first
identified in 2003 [51, 52]. MCP mutations were evaluated
in three families [51] with a second group reporting a mu-
tation in one family [52]. At present, at least 52 mutations
linked to development of aHUS and 13 to other diseases
have been reported (Tables 1 and 2). Mutations in MCP
are found in ~10–20 % of aHUS patients. Most mutations
are missense but nonsense, and splice-site variants are also
observed (reviewed in [40, 43, 46, 48, 53–55]). The major-
ity are also commonly rare, novel, and deleterious.
In about 75 % of cases, the mutant protein is not
expressed. In the remainder, the aberrant protein is
expressed but has a reduced or absent function, i.e.,
C3b- or C4b-binding and/or cofactor activity. Reduced
cofactor activity for C3b impairs proper regulation of
the AP. In addition to MCP mutations, a specific SNP
haplotype block termed the MCPggaac haplotype in
the MCP promoter region may be associated in vitro
with reduced transcriptional activity (reviewed in [43]).
This has been linked with an increased risk of aHUS
but only in the setting of a causative variant in another
AP component or regulator.
Other diseases
Mutations in MCP associated with diseases other than
aHUS have been noted (Table 2). These studies involve a
small number of patients and all will require confirm-
ation by further investigations.
Systemic sclerosis is an autoimmune disease character-
ized by immune system activation, microvascular dys-
function, and tissue fibrosis. Scambi et al. reported an
association between abnormally low CD46 expression in
skin vessels in a subset of patients with two polymorphic
variants (−366A >G, rs2796268 and −652A >G, rs2796267)
in the MCP promoter [56]. These two SNPs have also been
linked to enhanced severity of aHUS [38, 39].
Nonsynonymous MCP mutations (S13F and A219V)
were implicated in earlier development of nephritis, but
were not predisposing to systemic lupus erythematosus
(SLE) or nephritis [57]. The A353V (rs353665573) is an
uncommon polymorphism (1–5 %) that has been re-
ported to be associated with aHUS and several other dis-
eases discussed below. The S13F MCP mutation is also
associated with development of the HELLP syndrome
that features a combination of hemolysis, elevated liver
enzymes, and low platelets [58]. This disorder occurs in
about 0.5–0.9 % of all pregnancies and in 5–10 % of pa-
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Fig. 5 Disease-associated CD46 mutations. A schematic depicting CD46 protein, genomic organization, and disease-associated amino acid mutations.
CD46 has a 34-amino-acid signal peptide (SP). The mature protein consists of four complement control protein (CCP) repeats that house the sites for
regulatory activity. This is followed by an alternatively spliced region for O-glycosylation (segments A, B, C), a segment of undefined function (U), a
transmembrane domain (TM), and one of two alternatively spliced cytoplasmic tails (CYT-1 or CYT-2). The gene consists of 14 exons and 13 introns for
a minimum length of 43 kb. A majority of mutations for aHUS and for other disorders (such as systemic sclerosis, systemic lupus erythematosus, and
pregnancy-related disorders) occur in the four CCPs. Black, aHUS mutations; red, aHUS and other diseases; green, non-aHUS disease
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Table 1 CD46 mutations associated with aHUS and functional consequences
Mutation# Domain Functional studies Notes Refs
M1K SP Reduced expression [69]
S13F SP ND [70]
Y29X SP ND Compound heterozygote with factor H mutation [43, 53]
D33H SP ND [46]
IVS1 − 1G > C CCP1 Reduced expression Aberrant splicing of 2 bp after normal splice site;
premature stop codon C35X
[36, 43, 47, 48]
IVS2 + 2 T > G CCP1 Reduced expression Deleted 144 bp and 48 amino acids in phase with
wild-type
[36, 43, 47, 48, 71]
IVS2 + 1G > C CCP1 Reduced expression [39, 38, 71, 48, 43]
C35X CCP1 Reduced expression [43, 72]
C35Y CCP1 Reduced expression [43, 47, 48, 71]
E36X CCP1 Reduced expression [43, 71]
P50T CCP1 ND [43, 72]
Y54C CCP1 ND Successful treatment with eculizumab; transplanted [73]
R59X CCP1 Reduced expression [43, 46, 47, 71, 74]
C64F CCP1 Reduced expression Varicella trigger; 16 y/o successfully treated with
plasma exchange
[43, 75, 76]
K65D-fsX73 CCP1 ND [43, 53]
c. 286 + 2 T > G Between
CCP1-2
ND Frameshift leads to stop in CCP2 [45]
IVS2 − 2A > G CCP2 Reduced expression c. 287 − 2A > G;
Lacks exon 3 and creates stop codon at L133X;
[36, 43, 45, 47, 48,
71, 77–79]
C99R CCP2 Reduced expression [43, 47, 48]
R103W CCP2 Normal expression & C3/C4 regulatory
activity
[38, 39, 43, 48, 61, 71]
R103Q CCP2 ND Compound heterozygote with factor H mutation [43, 53]
Y117X CCP2 Reduced expression [46, 69]
G130V CCP2 ND [43, 53]
G135D CCP2 Reduced expression [69]
G135V-fsX13 CCP2 ND [43, 74]
P165S CCP3 Reduced expression [38, 39, 43, 48, 53]
E179Q CCP3 Normal to higher expression; 50 % loss
regulatory activity
[36, 43, 48]
D185N/Y189D CCP3 Reduced expression [36, 43, 48]
Y189D CCP3 Reduced expression [43, 45, 48, 70–72, 80]
G196R CCP3 Reduced expression; decreased C4b CA
only (FI interaction site)
[36, 48, 53, 73, 81]
G204R CCP3 ND [43, 53]
S206P CCP3 ND [43, 53]
I208Y CCP3 ND Compound heterozygote with factor H mutation [43, 53]
C210F CCP3 ND Compound heterozygote with factor-I mutation [43, 53]
W216C CCP3 ND Near functional site per [44] [43, 45]
P231R CCP4 ND Functional site per [44] [43, 45]
E234K CCP4 ND [46]
S240P CCP4 Normal expression; loss of C3b CA &
binding
Originally numbered S206P [43, 48, 51]
F242C CCP4 Normal expression; reduced C3b/C4b
binding and CA
[43, 45, 48, 53, 72]
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Preeclampsia complicates 4–5 % of pregnancies world-
wide, causing significant maternal and neonatal mortality.
Pregnancy in women with systemic lupus erythematosus
(SLE) and/or the antiphospholipid syndrome (APS) may
be particularly susceptible to complement-mediated injury
with increased risk of preeclampsia, placental insuffi-
ciency, retardation, fetal growth issues, and miscarriage. A
study analyzing a SLE and/or APL Ab cohort (PRO-
MISSE)-sequenced genes for complement FI, FH, and
MCP and found heterozygous mutations in seven (18 %)
[59]. Five had risk variants that had been previously
identified in aHUS, and one had a novel mutation in
CD46, K66N (identified as K32N in the paper since the
34 amino acid signal peptide was not counted) that im-
pairs only regulation of C4b. The study suggested a
linkage between excessive complement activation and
disease pathogenesis in patients with SLE and/or APL
Ab who develop preeclampsia.
Idiopathic, recurrent miscarriage has also been associ-
ated with mutations both in MCP and C4b-binding pro-
tein (C4BP) [60]. All exons coding for CD46, C4BP, and
decay-accelerating factor (DAF; CD55) were sequenced
in a cohort of 384 childless women with at least two
miscarriages. In addition to the first-time identification
of a disease association of C4BP mutation, four MCP
variants were identified. One of the rare variants, P324L,
had decreased expression, while N213I had both im-
paired expression and function. Two mutations that did
not appear to affect complement regulatory function
were located in the transmembrane domain, and a third
one was in the cytoplasmic tail that could impair signal-
ing function [6, 60, 61].
Of the ~ eight known aHUS cases of homozygous
CD46 deficiency, three also developed common variable
immunodeficiency [36, 37]. The remaining five patients
all presented with subnormal IgG1 levels. T cells from
CD46-deficient patients were not capable of promoting B-
cell responses suggesting a defect in the ability to optimize
B cell responses could account for this disease [37].
Mutation screening was also undertaken in 19 patients
with C3 glomerulonephritis (a form of glomeruloneph-
ritis characterized by mesangial C3 deposits) [62]. One pa-
tient was a compound heterozygote for MCP mutations in
both exon 5 (V215M in CCP3) and exon 11 (A353V in the
transmembrane domain). The V215M (termed V181M in
the paper) mutation occurred in a site determined to be
functionally important in a previous investigation [44].
Studies in the last decade have demonstrated how dys-
regulation of the AP contributes to age-related macular
degeneration (AMD) (reviewed in [63–67]). It is a lead-
ing worldwide cause of central vision loss in individuals
over the age of 50. Hypomorphs (i.e., genetically-based
changes resulting in functionally deficient complement
inhibitors that control the alternative pathway) account
for ~50 % of the attributable genetic risk for AMD. Al-
though no mutations have yet been identified linking
Table 1 CD46 mutations associated with aHUS and functional consequences (Continued)
Y248X CCP4 Reduced expression [43, 48, 52, 71, 72]
Y248C CCP4 ND [46]
K249N-fsX5 CCP4 ND [46]
G259V CCP4 Reduced expression; reduced C3b/C4b
binding and CA
Compound heterozygote with FH mutations [82]
L262P CCP4 Reduced expression aHUS pts successfully treated with eculizumab; [83]
T267-fs270X CCP4 Reduced expression delA843-C844 [43, 48, 52, 72]
Del D271/S272 CCP4 Reduced expression Originally numbered D237/S238 [43, 48, 51, 84]
c.852-856del CCP4 Reduced expression Originally numbered as 903-907del [38, 39, 43, 48]
858-872del +
D277N + P278S
CCP4 Reduced expression [43, 47, 48]
IVS10 + 2 T > C TM Reduced expression Exon 10 skipped changing aa 316–321 & adding a
stop at 322
[43, 71, 74]
c.983-984delAT TM ND Frameshift with stop [43, 45]
A353V TM Normal expression and complement
regulatory function
Uncommon variant; numerous studies and several
disease implications; sometimes termed A304V
[43, 47, 48, 61]
A359V TM ND Japanese pt; compound heterozygote with Y189D
in CCP3
[70]
T383I CYT-1 ND Fatal infections triggered aHUS in 2 patients. Mother
massive viral infection; son by E. coli O157:H7
[43, 53, 69]
#Numbered from SP and using ABC1 isoform or as noted for CYT-1. Abbreviations: SP signal peptide (34 amino acids), CCP1-4 complement control protein modules
1–4, UN Segment of unknown function proximal to membrane (12 amino acids), TM transmembrane domain, CYT-1 cytoplasmic tail 1 (16 amino acids), CA cofactor
activity, ND not done
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AMD and CD46, several studies suggest it may have a role
(reviewed in [67]). CD46 is found in drusen, the hallmark
of dry-type AMD. Lower expression is observed in the
monocytes of patients with AMD [67]. Further, smoking
has been directly linked to development of AMD, and
cigarette smoke extract decreased CD46 expression in ret-
inal epithelial cells [67]. A mouse model that knocked out
CD46 (Cd46−/−) found increased levels of membrane-
attack complex, and vascular endothelial growth factors
were increased in the retina and choroid of mice deficient
in CD46 [67]. Further, these mice also developed more se-
vere retinal damage in a laser induced model of AMD [67].
Conclusion
Rare and uncommon mutations in MCP lead to develop-
ment of aHUS and possibly several other diseases such
as pregnancy-related disorders and SLE. The patho-
physiological implications of the defective functioning of
CD46 in aHUS relate to an inability to sufficiently con-
trol the alternative pathway of complement. Incomplete
penetrance of mutations is 50 %, indicating that add-
itional genetic or environmental triggers are involved.
For aHUS, the outcome for renal transplantation with a
normal CD46 kidney is much more favorable than for
other mutations in complement proteins (reviewed in
[43, 47]). Additionally, the availability of a new thera-
peutic option for aHUS, the treatment with a mAb to
C5 (eculizumab), induces a remission in most patients
(reviewed in [49, 68]). With the advent of whole exome
and whole genome sequencing reaching more reasonable
costs, and in view of other putative conditions associated
with CD46, additional disease associations are likely on
the horizon.
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